Bellevue Group Ag Halozyme Therapeutics, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $2.31 Million - $3.92 Million	-70,300 Reduced 8.65%	742,400 $28.4 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $4.72 Million - $7 Million	-117,800 Reduced 12.66%	812,700 $46.2 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $1.57 Million - $2.11 Million	-40,800 Reduced 4.2%	930,500 $36.8 Million
Q2 2022 Aug 11, 2022	SELL	$37.35 - $48.3 $1.98 Million - $2.56 Million	-52,900 Reduced 5.17%	971,300 $42.7 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $1.38 Million - $1.78 Million	-43,300 Reduced 4.06%	1,024,200 $40.8 Million
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $4.65 Million - $5.95 Million	146,000 Added 15.84%	1,067,500 $42.9 Million
Q3 2021 Nov 12, 2021	SELL	$38.47 - $46.42 $50.1 Million - $60.5 Million	-1,302,966 Reduced 58.57%	921,500 $37.5 Million
Q2 2021 Aug 12, 2021	SELL	$38.84 - $51.31 $30.6 Million - $40.4 Million	-787,500 Reduced 26.15%	2,224,466 $101 Million
Q1 2021 May 12, 2021	SELL	$39.51 - $51.45 $40.8 Million - $53.1 Million	-1,033,034 Reduced 25.54%	3,011,966 $126 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $36.8 Million - $62.1 Million	-1,424,131 Reduced 26.04%	4,045,000 $173 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $32.5 Million - $37.4 Million	-1,261,421 Reduced 18.74%	5,469,131 $144 Million
Q2 2020 Aug 13, 2020	SELL	$16.25 - $26.81 $15.2 Million - $25 Million	-933,404 Reduced 12.18%	6,730,552 $180 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $5.18 Million - $8.14 Million	-372,900 Reduced 4.64%	7,663,956 $138 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $335,925 - $439,425	22,500 Added 0.28%	8,036,856 $142 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $3.55 Million - $4.13 Million	-233,504 Reduced 2.83%	8,014,356 $124 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $122 Million - $142 Million	8,247,860 New	8,247,860 $142 Million
Q2 2018 Aug 07, 2018	SELL	$16.87 - $20.3 $1.28 Million - $1.54 Million	-75,800 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$17.06 - $21.2 $20,472 - $25,440	-1,200 Reduced 1.56%	75,800 $1.49 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $177,550 - $220,480	-10,600 Reduced 12.1%	77,000 $1.56 Million
Q3 2017 Nov 13, 2017	SELL	$11.76 - $17.4 $1.55 Million - $2.29 Million	-131,400 Reduced 60.0%	87,600 $1.52 Million
Q2 2017 Aug 14, 2017	BUY	N/A	219,000	219,000 $2.81 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$613 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$315 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$193 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$162 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account